Minimal Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients
Dolutegravir can be safely administered to HIV-infected patients with advanced kidney disease (GRF
Abstracts
Dolutegravir can be safely administered to HIV-infected patients with advanced kidney disease (GRF
Efavirenz (EFV) 600mg is currently recommended by WHO as a first-line antiretroviral agent in HIV infected adults. A dose reduction to 400mg EFV has been proposed because of concerns regarding toxicitity. EFV is widely used during pregnancy in those countries where HIV infection is most common. Pregnancy can reduce exposure to antiretroviral agents with a…
Nigeria has an estimated 3.1 million people living with HIV (PLWH), accounting for nearly 10% of global HIV burden. Use of traditional medicines is high in the general population. Here, we sought to evaluate the use of herbal medicines amongst (PLWH), and undertake a country-wide analysis of herbal medicines used by PLWH for possible contamination…
One of the highest priorities of HIV research is to have access to long-acting pharmaceutical formulations for HIV treatment and prevention. Our research aims at fabrication of combination antiretroviral (cARV) drugs loaded nano-system for PReP. Presently we report on the pharmacokinetics of tenofovir disoproxil fumurate (TDF) and elvitegravir (EVG) loaded nanoparticles (TDF+EVG NP) in humanized mice (huNSG). Formulation of cARV…
HIV Prevention Trials Network 043 (NIMH Project Accept) was a community-randomized trial in Africa and Thailand that assessed the impact of behavioral interventions on HIV incidence. Interventions were delivered over 3 years. HIV incidence was then assessed in a cross-sectional survey of >50,000 randomly-sampled adults (survey period: 2009-2011). At the African sites (34 communities at…
MK-8591 is a nucleoside reverse transcriptase translocation inhibitor (NRTTI) in early clinical development. MK-8591-triphosphate (TP), the active phosphorylated anabolite of MK-8591, exhibited protracted intracellular persistence in human and monkey peripheral blood mononuclear cells (PMBCs) in vitro. In preclinical experiments, MK-8591 administered once-weekly in an SIV rhesus macaque model demonstrated potent antiviral efficacy. Clinically, MK-8591-TP exhibited…
To ensure sustainability of antiretroviral treatment (ART) programmes after ART scale up, the WHO has proposed a global standardized HIV drug resistance (DR) monitoring and surveillance strategy, including the assessment of pre-treatment HIVDR (PDR). We present the first nationally representative WHO HIV PDR survey performed in Mexico from February to July 2015. Twenty-five clinics were…
HIV drug resistance detected during acute infection may be a result of transmission from an infected partner, selection by pre-exposure prophylaxis (PrEP), or error prone replication. Here we describe the long-term dynamics of resistance detected during early acute HIV infection. The Partners PrEP Study was a randomized trial in which serodiscordant partners were assigned to…
Background: Integrase inhibitors (INIs), including raltegravir (RGV), elvitegravir (EVG) and dolutegravir (DTG) are a drug class of choice in first-line therapy. Emergent resistance to EVG and RGV include N155H and G140A/G148RHQ pathways, conferring RGV/EVG cross-resistance, and Y143RHC (RGV) and T66I/E92Q/G (EVG) pathways. To date, DTG shows a higher barrier to resistance with no reported mutations…
National transmitted HIV-1 drug resistance (TDR) rates are typically monitored through HIV surveillance data and this represents the gold-standard for determining TDR rates in various populations. However, it often requires several years to prepare data for presentation and publication resulting in long lag times between data accumulation and result dissemination. Here we present a computational…